Sign in Subscribe
Drugs

Thousands of Jobs Under Threat as Zeneca and Astra Merger Confirmed

Strategic Insights

— 1 min read

The merger between British drug giant Zeneca and Swedish rival Astra has been confirmed, resulting in a massive $41 billion deal that threatens up to 1000 jobs in Britain and 5000 more worldwide. The new company, AstraZeneca, will be the third largest pharmaceuticals group worldwide, with a strong presence in the US and Europe. The combined group will have total sales of $10 billion and will spend over $1 billion annually on research and development.

Key Takeaways:

  • The merger between Zeneca and Astra will result in up to 1000 job losses in Britain and 5000 more worldwide over the next three years.
  • Zeneca's agrochemical plant at Grangemouth is under threat, with 1250 jobs potentially at risk.
  • Astra has a clinical research unit in Edinburgh that employs 50 people, but the jobs situation at this site is unclear.
  • The new company, AstraZeneca, will have total sales of $10 billion and will be the third largest pharmaceuticals group worldwide in terms of sales and marketing operations.
  • AstraZeneca will have combined drug sales of over $6 billion and will be the third largest in the world for research and development.
  • The merger will create $666 million in annual cost savings after three years.
  • Zeneca's shares rose by 210p to $27.30 on the news of the merger.
  • The board of directors of AstraZeneca will be drawn equally from the two companies, with Zeneca's Tom McKillop becoming chief executive.

Statistics:

  • Up to 1000 jobs in Britain are under threat as a result of the merger.
  • 5000 jobs worldwide are expected to be lost over the next three years.
  • 1250 jobs at Zeneca's agrochemical plant at Grangemouth are potentially at risk.
  • AstraZeneca will have total sales of $10 billion.
  • Combined drug sales will exceed $6 billion.
  • AstraZeneca will spend over $1 billion annually on research and development.
  • The merger will create $666 million in annual cost savings after three years.

Sources:

  • "Zeneca and Astra Agree $41bn Merger." BBC News, 29 Apr. 1999.
  • "AstraZeneca: The New Phoenix from the Ashes." Financial Times, 30 Apr. 1999.

Read more